BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 556 filers reported holding BIO-TECHNE CORP in Q3 2021. The put-call ratio across all filers is 1.21 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,572,140 | -20.4% | 140,622 | -4.5% | 0.01% | -14.3% |
| Q2 2023 | $12,023,283 | +46.4% | 147,290 | +33.1% | 0.01% | +40.0% |
| Q1 2023 | $8,212,907 | -32.4% | 110,701 | -24.2% | 0.01% | -37.5% |
| Q4 2022 | $12,144,980 | +18.8% | 145,964 | +305.9% | 0.01% | +14.3% |
| Q3 2022 | $10,225,453 | -18.5% | 35,962 | -0.6% | 0.01% | -22.2% |
| Q2 2022 | $12,550,842 | -15.0% | 36,176 | +6.6% | 0.01% | -10.0% |
| Q1 2022 | $14,757,813 | -16.0% | 33,950 | -0.3% | 0.01% | -9.1% |
| Q4 2021 | $17,568,000 | -1.1% | 34,040 | -7.2% | 0.01% | -26.7% |
| Q3 2021 | $17,768,000 | -7.3% | 36,668 | -13.8% | 0.02% | -6.2% |
| Q2 2021 | $19,164,000 | +15.3% | 42,562 | -2.2% | 0.02% | +14.3% |
| Q1 2021 | $16,626,000 | +12.8% | 43,531 | -6.2% | 0.01% | 0.0% |
| Q4 2020 | $14,744,000 | +17.8% | 46,429 | -8.1% | 0.01% | +7.7% |
| Q3 2020 | $12,516,000 | -46.7% | 50,523 | -45.4% | 0.01% | -40.9% |
| Q2 2020 | $23,489,000 | +121.2% | 92,549 | +65.3% | 0.02% | +83.3% |
| Q1 2020 | $10,617,000 | -11.9% | 55,990 | +2.0% | 0.01% | -7.7% |
| Q4 2019 | $12,048,000 | -9.7% | 54,885 | -18.8% | 0.01% | -13.3% |
| Q3 2019 | $13,336,000 | -24.4% | 67,582 | -20.2% | 0.02% | -28.6% |
| Q2 2019 | $17,646,000 | +10.4% | 84,641 | +5.1% | 0.02% | +23.5% |
| Q1 2019 | $15,984,000 | +33.8% | 80,505 | -2.5% | 0.02% | +13.3% |
| Q4 2018 | $11,947,000 | -25.4% | 82,552 | +5.2% | 0.02% | -11.8% |
| Q3 2018 | $16,019,000 | +26.0% | 78,480 | -8.7% | 0.02% | +21.4% |
| Q2 2018 | $12,714,000 | -6.4% | 85,929 | -4.4% | 0.01% | -6.7% |
| Q1 2018 | $13,582,000 | +18.3% | 89,922 | +1.5% | 0.02% | +25.0% |
| Q4 2017 | $11,479,000 | +16.9% | 88,604 | +9.1% | 0.01% | 0.0% |
| Q3 2017 | $9,820,000 | -1.2% | 81,235 | -4.0% | 0.01% | 0.0% |
| Q2 2017 | $9,940,000 | +22.4% | 84,605 | +5.9% | 0.01% | +20.0% |
| Q1 2017 | $8,118,000 | +55.5% | 79,868 | +57.3% | 0.01% | +42.9% |
| Q4 2016 | $5,221,000 | -6.7% | 50,772 | -0.6% | 0.01% | -12.5% |
| Q3 2016 | $5,595,000 | -1.3% | 51,095 | +1.6% | 0.01% | -11.1% |
| Q2 2016 | $5,671,000 | +20.9% | 50,288 | +2.4% | 0.01% | +125.0% |
| Q1 2016 | $4,692,000 | +8.4% | 49,101 | +2.1% | 0.00% | 0.0% |
| Q4 2015 | $4,329,000 | -3.3% | 48,109 | -0.6% | 0.00% | -20.0% |
| Q3 2015 | $4,477,000 | -8.0% | 48,419 | -2.0% | 0.01% | -16.7% |
| Q2 2015 | $4,865,000 | +1.2% | 49,407 | +3.1% | 0.01% | 0.0% |
| Q1 2015 | $4,805,000 | +10.2% | 47,908 | +1.5% | 0.01% | 0.0% |
| Q4 2014 | $4,362,000 | – | 47,211 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |